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OBJECTIVES: Chronic disease imparts signiﬁcant disability, pre-
mature mortality and economic burden on countries. Chronic
obstructive pulmonary disease (COPD) will be the ﬁfth leading
cause of disability-adjusted mortality in 2020. Causative expo-
sures include tobacco smoke, biomass fuels, occupational and
other environmental factors. The Burden of Obstructive Lung
Disease (BOLD) project will estimate the prevalence and burden
of COPD globally. Here, we on the design, development and
application of a population simulation model to forecast
country-speciﬁc economic burden of COPD. To show feasibility
of the model, we report US burden data. METHODS: A pub-
licly available population simulation model was developed to
estimate annual and future mortality and costs. The model
reﬂects changes in the size, composition and population demo-
graphics of the jurisdiction. Input data include disease prevalence
from the BOLD COPD epidemiology studies, tobacco smoking
and cessation rates, background mortality, disease attributable
mortality, annual incidence of COPD, lung function progression
data from the Framingham Heart Study and costs. Simulations
are based on a starting cohort age 20 years and older in 2005.
Five, 10 and 20-year projections are discounted at 3% per year.
RESULTS: The model projects COPD prevalence to increase
each year. In 2005, the projected cost of COPD in the US was
$51.4 billion in medical expenses or $256 per capita. Cumula-
tive discounted 5, 10 and 20 year medical costs for COPD were
$304.9 billion, $678.4 billion and $1415.3 billion. CONCLU-
SIONS: COPD is one of the world’s leading causes of disability
and mortality. The economic consequences of tobacco use and
occupational exposures leading to COPD are substantial. We
developed this model as part of a global burden identiﬁcation
and reduction project. Here, we show its application for burden
simulation with US data, but intend a larger global effort in con-
junction with the BOLD project.
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OBJECTIVES: To compare direct medical costs related to 
the management of community acquired pneumonia (CAP) 
and acute exacerbations of chronic bronchitis (AECB) 
between telithromycin (TEL) and clarithromycin (CLA) or
amoxicillin/clavulanic acid (AMC), in both public and private
sector in Greece. METHODS: A health outcomes model was
developed from three Phase III multinational clinical studies
comparing TEL with CLA in CAP, and with AMC in AECB. In
each study patients were followed for 36 days and the primary
endpoint was clinical efﬁcacy at post therapy visit. Health care
resources included in the model were additional non-protocol
antibiotics, hospitalizations, laboratory tests and outpatient
health care professional visits. Two cost analyses were per-
formed; one from the perspective of Greek Health care System
by using public sector unit costs and one from private sector per-
spective in Greece (including both reimbursable costs and out of
pocket costs) in an effort to present a more realistic case for
Greece. RESULTS: From the Greek Health care System perspec-
tive, the use of TEL instead of CLA in CAP resulted in cost
savings of up to €49 per patient and up to €20 per patient when
compared with AMC in AECB. For the Greek private sector, TEL
cost differences were even greater, up to €71 when administered
for CAP instead of CLA and up to €28 in AECB instead of AMC.
The cost savings resulted from TEL patients required fewer non-
protocol additional health care resources (mainly a lower rate of
hospitalization and shorter length of stay) than the patients in
the comparator groups in both CAP and AECB. CONCLU-
SION: In Greece the use of telithromycin as a ﬁrst line treatment
option for CAP and AECB instead of clarithromycin or amoxi-
cillin/clavulanic acid respectively, may signiﬁcantly reduce health
care costs in both public and private sector.
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OBJECTIVE: Chronic obstructive pulmonary disease (COPD)
accounts for about 10% of patient visits to a pneumologist, 7%
of all hospital admissions, and 35% of permanent work disabil-
ity. The aim of this study has been to assess health care resources
utilization in Spain depending on the severity of the disease.
METHODS: This analysis has been carried out through the
design of a one-year retrospective naturalistic study performed
through the whole Spanish territory, including both urban and
rural areas. There have been included 9,045 COPD patients with
a mean age of 67 ± 9.8 years. The severity of the disease was as
follows: 33.8% mild (FEV1: 60–80% of predicted), 49.3% mod-
erate (FEV1: 40–60% of predicted) and 16.8% severe (FEV1 <
40% of predicted). Health care resources collected were: added
visits to the general practitioner (GP) and pneumologist, added
visits to the emergency room, length of stay in the hospital and
number of days off work. RESULTS: Severe COPD patients pre-
sented more added visits to the GP compared to moderate and
mild COPD patients (5.83, 4.65 and 3.25 respectively, p <
0.001), likewise with regard to added visits to the pneumologist
(1.55, 1.09 and 0.62 respectively, p < 0.001) and added visits to
the emergency room (2.50, 1.62 and 0.9 respectively, p < 0.001).
In addition, severe COPD patients showed a longer length of stay
in the hospital than moderate and mild COPD patients (16.7 vs.
10.9 and 8.8 days respectively, p < 0.001) and less days off work
(51.2, 29.4 and 18.9 respectively, p < 0.01). CONCLUSIONS:
Severe COPD patients require higher health care resources uti-
lization than moderate and mild patients. Therefore, it is neces-
sary to elaborate programs and policies focused in diagnosing
early COPD patients to try to avoid progression of mild patients
to moderate and severe stages of the disease.
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OBJECTIVES: To describe ARDS patients regarding survival,
ventilation status, predisposing events, disease characteristics,
length of hospital stay and duration of ventilation. METHODS:
In a phase III clinical trial investigating treatment with Venticute
(rSPC surfactant) compared to standard treatment in patients
hospitalized for ARDS (NEJM 351, 884–892, 2004), patients
were followed up for up to one year after randomization. This
analysis is focused on the initial hospitalization and describes the
pooled results from both treatment groups. Data were collected
for 197 patients by means of a speciﬁc questionnaire covering
